Objective:To investigate the contribution and efficiency of 18F-PSMA-1007 PET/CT in the evaluation of newly diagnosed prostate cancer(PCa).Methods:A total of 115 patients with newly diagnosed PCa who underwent 18F-PSMA-1007 PET/CT were retrospectively analyzed.PET/CT images were analyzed visually and semiquantitatively by measuring the SUVmax.The correlation between the Gleason score(GS),prostate-spe-cific antigen(PSA),metastatic extent and the SUVmax of the primary tumor was analyzed.A post-treatment sec-ond 18F-PSMA-1007 PET/CT scan was conducted in 7 patients to monitor treatment response.Results:The medi-an PSA of 115 patients was 43.9 ng/mL,and the median SUVmax of the primary lesion was(23.8±16.1).Among them,49 patients(42.61％)were ISUP 1-3 group and 66 patients(57.39％)were ISUP 4-5 group.Significantly higher tracer uptake in primary tumors was found in the subgroup ISUP 4-5 group(30.2±15.7)compared to the subgroup ISUP 1-3 group(15.0±12.1).Patients with PSA＜10 ng/mL(11.2±9.7)exhibited significantly lower tracer uptake in primary tumors than those with PSA ≥ 10 ng/mL(25.4±16.1).In addition,the SUVmax of primary tumors was found to be positively associated with the PSA level.Compared to the patients receiving PET/CT for disease restaging,multiple 18F-PSMA-1007 PET/CT results in newly diagnosed PCa patients were consistent with their disease state indicated by PSA level.Conclusion:Tracer uptake in the primary tumor on 18F-PSMA-1007 PET/CT was positively correlated with prognostic parameters,including GS and PSA.The multiple-scan application of 18F-PSMA-1007 PET/CT exhibited excellenttreatment response monitoring performance.
万方数据